These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16931916)

  • 21. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
    Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
    Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
    Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
    Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
    Azorsa DO; Gonzales IM; Basu GD; Choudhary A; Arora S; Bisanz KM; Kiefer JA; Henderson MC; Trent JM; Von Hoff DD; Mousses S
    J Transl Med; 2009 Jun; 7():43. PubMed ID: 19519883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
    Arlander SJ; Eapen AK; Vroman BT; McDonald RJ; Toft DO; Karnitz LM
    J Biol Chem; 2003 Dec; 278(52):52572-7. PubMed ID: 14570880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
    Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
    Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
    Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
    Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
    Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
    Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B.
    Zuazua-Villar P; Rodriguez R; Gagou ME; Eyers PA; Meuth M
    Cell Death Dis; 2014 May; 5(5):e1253. PubMed ID: 24853431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
    Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM; Flatten KS; Wagner JM; Loegering D; Hackbarth JS; Arlander SJ; Vroman BT; Thomas MB; Baek YU; Hopkins KM; Lieberman HB; Chen J; Cliby WA; Kaufmann SH
    Mol Pharmacol; 2005 Dec; 68(6):1636-44. PubMed ID: 16126823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.
    Xiao Z; Xue J; Gu WZ; Bui M; Li G; Tao ZF; Lin NH; Sowin TJ; Zhang H
    Biomarkers; 2008 Sep; 13(6):579-96. PubMed ID: 18671143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
    Zhang WH; Poh A; Fanous AA; Eastman A
    Cell Cycle; 2008 Jun; 7(11):1668-77. PubMed ID: 18469532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
    Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
    Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.